Anticoagulación en Niños Cardiópatas
Contenido principal del artículo
Resumen
Las enfermedades tromboembólicas han sido denominadas la nueva epidemia de los hospitales pediátricos del tercer nivel de atención. Siendo más evidente en los pacientes cardiacos y cardioquirúrgicos, que en ningún otro tipo de pacientes. Los niños tratados por presentar cardiopatía estructural desarrollan trombosis iatrogenicamente, frecuentemente precipitada por la presencia de catéter venoso central. El sistema de la hemostasia no se encuentra completamente desarrollado hasta los 6 meses de edad. Hay importantes diferencias fisiológicas en el sistema hemostático de los niños comparado con el de los adultos. Las complicaciones trombóticas, cuando ocurren en niños, son habitualmente eventos secundarios asociados a patologías subyacentes. La incidencia global de eventos tromboembólicos en niños se encuentra en aumento, estimándose un rango entre 0.07 a 28.8 casos por cada 10.000 admisiones pediátricas en general.
Este artículo revisa determinados procesos mórbidos pediátricos, los agentes antitrombóticos más frecuentemente utilizados en la población pediátrica, y la evidencia científica disponible para la prevención ante diferentes situaciones clínicas.Detalles del artículo
La revista no retiene los derechos de reproducción (copyright) por lo que los autores pueden volver a publicar sus trabajos con la sola mención a la fuente original de publicación.
Citas
1- Reller MD. Congenital heart disease: current indications for antithromotic therapy in pediatric patients. Curr Cardiol Rep 2001; 3:90-5.
2-Monagle P. Anticoagulation in the young. Heart 2004; 90:808-12.
3-Monagle P. Thrombosis in Pediatric Cardiac Patients. Sem Thromb Hemostas 2003; 29:547-56.
4-Boris JR, Harris MA. The use of anticoagulation in pediatric cardiac disease. Images Paediatr Cardiol 2003; 16:1-35.
5-Monagle P, Chalmers E, Chan A, et al. Antithrombotic Therapy in Neonates and Children. Chest 2008; 133:887S-968S.
6-Manrique AM, Sánchez Galindo A, Muñoz R. Hemostasia, Sangrado Postoperatorio y Anticoagulación. En: Muñoz R, Da Cruz E, Palacio G, Maroto C, editores. Cuidados Críticos en cardiopatías Congénitas o Adquiridas. Bogotá: Distribuna Editorial, 2007; p.107-17.
7-Moss, Adams. Heart disease in infants, children and adolescents. 5th ed. Williams & Wilkins, 1995: vol 1, Part A, Chap 6.
8-Hoffman JI, Kaplan S. The Incidence of Congenital Herat Disease. J Am Coll Cardiol 2002; 39:1890-900.
9-Mitchell L, Male C. Central venous line-related thrombosis in children with congenital heart disease: Diagnosis, prevalence, outcomes and prevention. Progress in Pediatric Cardiology 2005; 21(1): 9-16.
10-Massicotte MP, Chair PO. Evidence based recommendation for anticoagulation in children with congenital heart disease (Primary prophylaxis: cardiac catheterization, mechanical heart valves, cardiac shunts, central lines and Secondary prophylaxis: Systemic thrombosis and stroke). Progress in Pediatric Cardiology 2005; 21(1):123-7.
11-Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, and Mitchell L. Maturation of the Hemostatic System During Childhood. Blood 1992; 80:1998-2005.
12- Kuhle S, Massicotte PM. Maturation of the coagulation system during childhood. Progress in Pediatric Cardiology 2005; 21(1): 3-7.
13-Mitchell L, Piovella F, Ofosu F, Andrew M. Alpha-2- Macroglobulin may provide protection from thromboembolic events in antithrombin III deficient children. Blood 1991; 78(9):2299-2304.
14- Jacobs ML and Pourmoghadam KK. Thromboembolism and the Role of Anticoagulation in the Fontan Patient. Pediatr Cardiol 2007; 28:457-462.
15- Pérez-Gómez F, Bover R. La nueva cascada de la coagulación y su posible influencia en el difícil equilibrio entre trombosis y hemorragia. Rev Esp Cardiol 2007; 60(12):1217-9.
16- Caterina RD, Husted S, Wallentin L, et al; for the Task Force of the European Society of Cardiology. Eur Heart J 2007; 28:880-913.
17-Levi M, ten Cate H, van der Poll T. Endothelium: Interface between coagulation and inflammation. Crit Care Med 2002; 30(5, Suppl.): s220-s224.
18- Yeh T, Karavana MN. Cardiopulmonary bypass and the coagulation system. Progress in Pediatric Cardiology 2005; 21(1): 87-115.
19-Taggart DP, Hadjinikolas L, Wong K, et al. Vulnerability of paediatric myocardium to cardiac surgery. Heart 1996; 76:214-7.
20-Hammer S, Loeff M, Reichenspurner H. Effect of Cardiopulmonary Bypass on
Myocardial Function, Damage and Inflammation after Cardiac Surgery in Newborns
and Children. Thorac cardiovasc Surg 2001; 49: 349-354.
21-Coleman N, Slonim AD. Venous thromboembolism in children: Are we targeting a real o imagined risk?. Pediatr Crit Care Med 2009; 10(5):602-4.
22-Ignjatovic V, Summerhayes R, Than J, et al. Therapeutic range for unfractioned heparin therapy: age-related differences in response in children. J Thromb Haemost 2006; 4:2280-2.
23-Smugge M, Resch L, Huber AR, et al. Heparin Induced Thrombocytopenia Associated Thrombosis in Pediatric Intensive Care Patients. Pediatrics 2002; 109:e10.
24-Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparina in pediatric patients: a prospective cohort study. J Pediatr 2000; 136:439-45.
25-Israels SJ, Michelson AD. Antiplatelet therapy in children. Thromb Res 2006; 118:75-83.
26- Li J, Berezny K, Yow E, et al. Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children. Primary results of the PICOLO trial. Circulation 2008; 117:553-9.
27-Williams RV, Wilke VM, Tani LY, et al. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002; 109:E4.
28-Wells WJ, Yu Rj, Batra AS, et al. Obstruction in modified Blalock shunts: a quantitative analysis with clinical correlation. Ann Thorac Surg 2005; 79:2072-6.
29- Paul Monagle. Thrombosis in children with BT shunts, Glenns and Fontans. Progress in Pediatric Cardiology 2005; 21(1):17-21.
30-Li JS, Yow E, Berezny KY, Rhodes JF, et al. Clinical outcomes of palliative surgery including a systemicto–pulmonary artery shunt in infants with cyanotic congenital heart
disease: does aspirin make a difference? Circulation. 2007;116:293–297.
31-Kopf G, Laks H, Stancel H, et al. Thirty-year follow-up of superior vena cava-pulmonary artery (Glenn) shunts. J Thorac Cardiovasc Surg 1990; 100:662-70.
32-Konstantinov IE, Puga FJ, and Alexi-Meskishvili VV. Thrombosis of intracardiac or extracardiac conduits after modified Fontan operation in patients with azygous continuation of the inferior vena cava. Ann Thorac Surg 2001; 72: 1641-4.
33-Chun DS, Schamberger MS, Flaspohler T, et al. Incidence, outcome, and risk factors for stroke after the Fontan procedure. Am J Cardiol 2004; 93:117-9.
34-Odegard KC, Zurakowski D, Di Nardo JA, et al. Prospective longitudinal study of coagulation profiles in children with hypoplastic left Herat síndrome from stage I through Fontan completion. J Thorac Cardiovasc Surg 2009; 137:934-941.
35- Harmon WG. Sleeper LA, Cuniberti L, et al. Treating Children With Idiopathic Dilated Cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am J Cardiol 2009; 104:281-6.
36-Donti A, Formigari R, Ragni L, et al. Pulmonary arterial hypertens in the Pediatric age. J Cardiovasc Med (Hagerstown). 2007;8(1):72-7. (Abstract)
37-ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53:1573-1619.
38-Adiata I, Shekerdemian L. The role of calcium channel blockers, steroids, anticoagulation, antiplatelet drugs, and endothelin receptor antagonists. Pediatr Crit Care Med 2010; 11(Suppl.):S46-S52.
39-Salem DN, O´Gara PT, Madias C, Pauker SG. Valvular and Structural Heart Disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S-629S.
40-Fred MD, Keane JF, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterisation in children. Circulation 1974; 50:565-9.
41- Wood LE, Tulloh RMR. Kawasaki disease in children. Heart 2009; 95:787-792.
42-Durongpisitkul, Kritvikrom, Gururaj, Vymutt J., Park, Joon M., Martin, Clyde
F. The Prevention of Coronary Artery Aneurysm in Kawasaki Disease: A Meta-
analysis on the Efficacy of Aspirin and Immunoglobulin Treatment. Pediatrics 1995;
96: 1057-1061.
43-Wooditch, Angela C., Aronoff, Stephen C. Effect of Initial Corticosteroid
Therapy on Coronary Artery Aneurysm Formation in Kawasaki Disease: A Meta-
analysis of 862 Children. Pediatrics 2005; 116: 989-995.
44-Reich JD, Campbell R. Myocardial Infarction in Children. Am J Emerg Med 1998; 16:296-303.
45-Lane JR, Ben-Shachar G. Myocardial Infarction in Healthy Adolescents. Pediatrics 2007 120: e938-e943.
46-Losay J, Touchot A, Serraf A, et al. Late Outcome After Arterial Switch Operation for Transposition of the Great Arteries. Circulation 2001; 104(suppl I):121-6.
47-Bacha EA, Quinones J, Kahana MD, et al. Embolic coronary occlusion after the arterial switch procedure. J Thorac Cardiovasc Surg 2001; 122(5)1028-30.